Nyrada Inc – Cholesterol-Lowering Program Preclinical Development Update

• Preclinical dose formulation work has been completed
• Toxicology studies have been completed, safety and pharmacology studies to be finalised by the end of April
• Phase I/IIa first-in-human study expected to start early 2H CY2023
• Nyrada appoints Mr. Seth Gordon, a former pivotal member of the Lipitor® marketing team at Pfizer, as Principal Consultant to advise on program strategy and asset development